Sionna Therapeutics (NASDAQ:SION) Trading 4.5% Higher – Still a Buy?

Shares of Sionna Therapeutics, Inc. (NASDAQ:SION) were up 4.5% during mid-day trading on Tuesday . The company traded as high as $12.91 and last traded at $12.65. Approximately 11,004 shares traded hands during trading, a decline of 95% from the average daily volume of 231,585 shares. The stock had previously closed at $12.10.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on SION. TD Cowen initiated coverage on Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a “buy” rating on the stock. Guggenheim assumed coverage on Sionna Therapeutics in a report on Tuesday, March 4th. They set a “buy” rating and a $45.00 price target for the company. Finally, Stifel Nicolaus assumed coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They issued a “buy” rating and a $32.00 price objective on the stock.

Sionna Therapeutics Price Performance

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Thursday, March 20th. The company reported ($3.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.68) by ($0.70).

About Sionna Therapeutics

We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.